Grufity logoGrufity logo

ACOR

0.61USD-0.02(-3.19%)Market Closed

Acorda Therapeutics Inc

Market Summary

USD0.61-0.02Market Closed
-3.19%

ACOR Stock Price

RSI Chart

Valuation

Market Cap

15.9M

Price/Earnings

-0.13

Price/Sales

0.13

Price/Cashflow

-0.47

MarketCap/EBT

-0.17

Price/Sales

Profitability

EBT Margin

-76.60%

Return on Equity

-135.19%

Return on Assets

-29.25%

Fundamentals

Revenue

Revenue (TTM)

124.1M

Revenue Y/Y

6.53%

Revenue Q/Q

7.92%

Earnings

Earnings (TTM)

-105.6M

Earnings Y/Y

48.82%

Earnings Q/Q

70.32%

Price Action

52 Week Range

0.262.79
(Low)(High)

Last 7 days

0.3%

Last 30 days

-15.1%

Last 90 days

53.6%

Trailing 12 Months

-76.6%

Financial Health

Current Ratio

1.86

Debt/Equity

1.72

Debt/Cashflow

-0.22

Investor Care

Shares Dilution (1Y)

117.26%

Diluted EPS (TTM)

-6.82

Peers (Alternatives to Acorda Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Acorda Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue1.7%124122123129130
  S&GA Expenses-5.8%108115117124129
  R&D Expenses-8.4%6771013
Earnings Before Taxes19.0%-75.72-93.46-96.73-109.07-176.33
Net Income11.1%-105.62-118.84-95.02-103.95-166.44
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-3.2%393406424455466
  Current Assets-6.3%72778010297
    Cash Equivalents-10.5%2123324636
  Inventory-0.5%1515151921
  Net PPE-6.5%33445
  Current Liabilities2.2%4241465468
  Long Term Debt-151----
Shareholder's Equity-13.8%7688128151164
  Retained Earnings-1.5%-955.41-941.56-894.88-870.36-849.79
  Additional Paid-In Capital0.0%1,0301,0291,0241,0231,016
Accumulated Depreciation-35----
Shares Outstanding26.7%171311--
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations21.1%-26.75-33.92-28.10-41.35-43.14
  Share Based Compensation-22.7%22334
Cashflow From Investing-0.2%7474-0.18745
Cashflow From Financing-1714.6%-69.654

Risks

What is the probability of a big loss on ACOR?

100%


Probability that Acorda Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Acorda Therapeutics stock will be more than 30% underwater in next one year.

90.4%


Probability that Acorda Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACOR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on ACOR

-42.3%


10-Year Cumulative Returns

-57.0%


7-Year Cumulative Returns

-65.5%


5-Year Cumulative Returns

-63.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ACOR?

FIve years rolling returns for Acorda Therapeutics.

Which funds bought or sold ACOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
181
181
-%
2022-11-15
IMA Wealth, Inc.
UNCHANGED
-
-
-
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
-6,000
9,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-14
MILLENNIUM MANAGEMENT LLC
REDUCED
-38.94
-88,000
57,000
-%
2022-11-14
BlackRock Inc.
REDUCED
-2.68
-26,000
40,000
-%
2022-11-14
SUSQUEHANNA INTERNATIONAL GROUP, LLP
NEW
-
8,000
8,000
-%
2022-11-14
TWO SIGMA SECURITIES, LLC
REDUCED
-17.39
-6,000
7,000
-%
2022-11-14
Verition Fund Management LLC
UNCHANGED
-
-2,000
4,000
-%

1–10 of 38

Latest Funds Activity

Are funds buying ACOR calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ACOR

Acorda Therapeutics News

Seeking Alpha

Acorda Therapeutics, Inc. (ACOR) Stock Price Today, Quote & News.4 days ago

ACOR Fair Value

Recent SEC filings of Acorda Therapeutics

View All Filings
Date Filed Form Type Document
Nov 14, 2022
10-Q
Quarterly Report
Nov 14, 2022
8-K
Current Report
Nov 07, 2022
DEFA14A
DEFA14A
Nov 04, 2022
8-K
Current Report
Nov 01, 2022
DEFA14A
DEFA14A
Nov 01, 2022
8-K
Current Report
Oct 31, 2022
DEFA14A
DEFA14A
Oct 31, 2022
DEFA14A
DEFA14A
Oct 28, 2022
8-K/A
Current Report
Oct 28, 2022
DEFA14A
DEFA14A

Latest Insider Trading transactions for ACOR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-03
Sabella Lauren M
SOLD (Taxes)
-601.378
0.398
-1,511
Chief Operating Officer
2022-09-03
Clem Kerry M
SOLD (Taxes)
-601.378
0.398
-1,511
Chief Commercial Officer
2022-03-17
COHEN RON
SOLD
-3,894.5
1.7014
-2,289
President and CEO
2021-09-03
COHEN RON
SOLD (Taxes)
-17,257.2
4.38
-3,940
President and CEO
2021-09-03
Morales Robert
SOLD (Taxes)
-1,962.24
4.38
-448
Interim PAO & PFO
2021-09-03
Sabella Lauren M
SOLD (Taxes)
-6,618.18
4.38
-1,511
Chief Commercial Officer
2021-03-03
Sabella Lauren M
ACQUIRED
-
-
11,125
Chief Commercial Officer
2021-03-03
BLANK BURKHARD
ACQUIRED
-
-
11,125
CMO and Head of R&D
2021-03-03
COHEN RON
ACQUIRED
-
-
29,000
President and CEO
2020-12-01
LAWRENCE DAVID
SOLD (Taxes)
-737.542
0.6464
-1,141
Chief, Bus. Ops & PAO

1–10 of 47

Ronald Cohen
130
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

ACOR Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total net revenues$ 33,511$ 31,456$ 87,096$ 92,104
Costs and expenses:    
Cost of sales11,00513,30325,77236,589
Research and development1,3831,9314,6029,054
Selling, general and administrative22,99729,62380,00295,959
Amortization of intangible assets7,6917,69123,07323,073
Change in fair value of derivative liability (288)(37)(868)
Changes in fair value of acquired contingent consideration(4,576)2,205(10,709)(4,224)
Total operating expenses38,50054,465122,703159,583
Operating loss(4,989)(23,009)(35,607)(67,479)
Other income (expense), net:    
Interest and amortization of debt discount expense(7,465)(7,167)(22,501)(22,697)
Interest income171384
Other income (expense)  1,2501
Realized loss on foreign currency transactions(1)(1)(1)(4)
Total other expense, net(7,449)(7,167)(21,214)(22,696)
Loss before taxes(12,438)(30,176)(56,821)(90,175)
(Provision for) benefit from income taxes(1,416)3,105(28,237)6,788
Net loss$ (13,854)$ (27,071)$ (85,058)$ (83,387)
Net loss per share—basic$ (0.57)$ (2.43)$ (4.69)$ (8.17)
Net loss per share—diluted$ (0.57)$ (2.43)$ (4.69)$ (8.17)
Weighted average common shares outstanding used in computing net loss per share—basic24,29011,13118,14810,204
Weighted average common shares outstanding used in computing net loss per share—diluted24,29011,13118,14810,204
Net Product Revenues    
Revenues:    
Total net revenues$ 29,964$ 27,851$ 76,023$ 81,297
Royalty Revenues    
Revenues:    
Total net revenues3,047$ 3,60510,573$ 10,807
License Revenue    
Revenues:    
Total net revenues$ 500 $ 500 

ACOR Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 20,696$ 45,634
Restricted cash13,23213,400
Trade accounts receivable, net of allowances of $888 and $1,012, as of September 30, 2022 and December 31, 2021, respectively14,69017,002
Prepaid expenses5,1116,574
Inventory, net15,25218,548
Other current assets2,711999
Total current assets71,692102,157
Property and equipment, net of accumulated depreciation2,8254,382
Intangible assets, net of accumulated amortization312,779335,980
Right of use asset, net of accumulated amortization5,5416,751
Restricted cash2556,189
Other assets24711
Total assets393,339455,470
Current liabilities:  
Accounts payable11,50510,845
Accrued expenses and other current liabilities26,70528,605
Current portion of liability related to sale of future royalties 4,460
Current portion of lease liabilities1,4548,186
Current portion of acquired contingent consideration2,3591,929
Total current liabilities42,02354,025
Convertible senior notes162,760151,025
Derivative liability 37
Non-current portion of acquired contingent consideration35,24147,671
Non-current portion of lease liabilities4,6124,086
Non-current portion of loans payable24,92927,645
Deferred tax liability42,22813,930
Other non-current liabilities5,7805,914
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at September 30, 2022 and December 31, 2021; no shares issued as of September 30, 2022 and December 31, 2021, respectively
Common stock, $0.001 par value per share. Authorized 61,666,666 shares at September 30, 2022 and December 31, 2021; issued 24,338,195 and 13,249,802 shares, including those held in treasury, as of September 30, 2022 and December 31, 2021, respectively2413
Treasury stock at cost (5,543 shares at September 30, 2022 and December 31, 2021)(638)(638)
Additional paid-in capital1,029,7051,023,136
Accumulated deficit(955,415)(870,357)
Accumulated other comprehensive loss2,090(1,017)
Total stockholders’ equity75,766151,137
Total liabilities and stockholders’ equity$ 393,339$ 455,470